Loading clinical trials...
Loading clinical trials...
Valsartan/Amlodipine 160/5 mg or 160/10 mg Versus Valsartan 160 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Valsartan 160 mg Monotherapy
Conditions
Interventions
valsartan/amlodipine
Locations
2
Germany
Investigative Centers, Germany
Novartis Pharmaceuticals
Basel, Switzerland
Start Date
October 1, 2004
Primary Completion Date
June 1, 2005
Completion Date
June 1, 2005
Last Updated
May 17, 2017
NCT02417740
NCT07480265
NCT07073820
NCT06876233
NCT06062394
NCT06899815
Lead Sponsor
Novartis
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions